Morepen Laboratories Ltd has filed an International patent under the Patent Cooperation Treaty (PCT) for manufacturing process of Desloratadine, the $500 million drug meant for treatment of allergy, cough and cold, the company informed BSE.

The Company is further working to file the Drug Master File (DMF) for the drug in the US market in order to obtain the US Food and Drug Administration (FDA) approval. The Company has also launched the generic version of the drug in the domestic market and is marketing the drug under the brand name 'DesNova'.

Speaking on the occasion, Sushil Suri, chairman and managing director, Morepen Laboratories said, "Entry into the Desloratadine market gives us access to the highly regulated US prescription segment, which we missed because of the Over the Counter (OTC) switch, it will further help us to be around whether it is generic OTC or prescription segment".